Bent Karsten Jakobsen

USPTO Granted Patents = 32 (Patent Applications = 22)

CIPO Patents = 11 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 20)

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 363(Granted Patents)

Location History:

Oxon, GB (2012)
Oxfordshire, GB (2008 - 2016)
Abingdon, GB (2008 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11929151 - Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex (2024-03-12),

2. 11739442 - TCR libraries (2023-08-29),

3. 11124556 - TCR libraries (2021-09-21),

4. 11017882 - Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex (2021-05-25),

5. 10576162 - Bifunctional polypeptides (2020-03-03),

6. 10517960 - Bifunctional polypeptides (2019-12-31),

7. 10420846 - Bifunctional polypeptides (2019-09-24),

8. 10130721 - Bifunctional polypeptides (2018-11-20),

9. 9822163 - High affinity NY-ESO T cell receptors (2017-11-21),

10. 9512197 - High affinity NY-ESO T cell receptors (2016-12-06),

11. 9447410 - T cell receptor display (2016-09-20),

12. 9279122 - T cell receptor display (2016-03-08),

13. 9255135 - High affinity HIV T cell receptors (2016-02-09),

14. 9156903 - High affinity NY-ESO T cell receptors (2015-10-13),

15. 9115372 - Cells expressing modified T cell receptor (2015-08-25),

Title: The Innovative Mind of Bent Karsten Jakobsen: Revolutionizing Peptide Binding and T Cell Receptors

Introduction:

Meet Bent Karsten Jakobsen, a brilliant inventor hailing from Abingdon, GB, whose innovative spirit has led to the creation of 32 patents. His groundbreaking work in predicting off-target binding of peptides and developing T cell receptor libraries has significantly advanced the fields of immunology and precision medicine.

Latest Patents:

1. Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex: Bent's method allows for the prediction of potential cross-reactivity of binding peptides administered to subjects by identifying binding motifs in target peptides. This innovation enhances the safety and efficacy of peptide-based therapies.

2. TCR libraries: Bent's creation of a library of particles displaying various T cell receptors, including TRAV12-2 and TRBV gene products, has opened new avenues for designing targeted immunotherapies with enhanced specificity and effectiveness.

Career Highlights:

Bent Karsten Jakobsen has made significant contributions to companies such as Immunocore Limited and Adaptimmune Limited, where his innovative ideas have shaped the development of novel therapeutics and diagnostic tools. His expertise in immunology and peptide interactions has driven these companies towards groundbreaking advancements in the field.

Collaborations:

Throughout his career, Bent has collaborated with esteemed professionals in the industry, including coworkers Yi Li and Peter Eamon Molloy. Together, they have synergized their expertise to push the boundaries of scientific discovery and bring cutting-edge technologies to the forefront of healthcare innovation.

Conclusion:

Bent Karsten Jakobsen stands as a testament to the power of innovation and dedication in revolutionizing the fields of peptide binding and T cell receptor research. His remarkable patents and collaborations exemplify his unwavering commitment to pushing the boundaries of knowledge and propelling scientific advancements for the betterment of society.

This text is generated by artificial intelligence and may not be accurate.